Iodine treatment Coronavirus infectio

Phase 1

• Conditions: SARS-CoV-2 infection causing COVID-19 disease; MedDRA version: 20.1Level: LLTClassification code 10022902Term: Iodide intoxicationSystem Organ Class: 100000004863; Therapeutic area: Diseases [C] - Virus Diseases [C02]

• Registration Number: EUCTR2020-001852-16-NL
• Lead Sponsor: Maxima MC

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-07-14
• Last Update Posted: 16 November 2020

Recruitment & Eligibility

• Status: Authorised-recruitment may be ongoing or finished
• Sex: All
• Target Recruitment: 224

Inclusion Criteria

All patients 18 years of age and older, admitted to our hospital and who are tested positive for SARS-CoV-2 infection, are recruited for the study.
Patiënts must be legally competent and able to read the patient's information letter and sign the informed consent form.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 60
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 164

Exclusion Criteria

Thyroid disease or treatment, like goiter, thyroidectomie, radioactive iodine, medication related to thyroid dysfunction or the use of Amiodaron.

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified